eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Draft Guidance for Industry; Availability: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics

Draft Guidance for Industry; Availability: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics

Document ID: FDA-2011-D-0432-0001
Document Type: Notice
Agency: Food And Drug Administration
Topics: No Topics associated with this document
Federal Register Number: 2011-15089
View Document:  View as format pdf View as format html

Details Information

Document Subtype: Notice of Availability
Received Date: June 17 2011, at 12:00 AM Eastern Daylight Time
Start-End Page: 35450 - 35451
Page Count: 2
Comment Start Date: June 17 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: August 16 2011, at 11:59 PM Eastern Standard Time

Comments

    View All
Total: 7
Sanofi-aventis U.S. Inc. - Comment
Posted: 09/26/2011     ID: FDA-2011-D-0432-0012

Aug 16,2011 11:59 PM ET
Bristol-Myers Squibb - Comment
Posted: 09/26/2011     ID: FDA-2011-D-0432-0011

Aug 16,2011 11:59 PM ET
Genentech, Inc. - Comment
Posted: 09/16/2011     ID: FDA-2011-D-0432-0003

Aug 16,2011 11:59 PM ET
Boehringer Ingelheim Pharmaceuticals, Inc. - Comment
Posted: 09/26/2011     ID: FDA-2011-D-0432-0007

Aug 16,2011 11:59 PM ET
AstraZeneca - Comment
Posted: 09/26/2011     ID: FDA-2011-D-0432-0008

Aug 16,2011 11:59 PM ET

Related Documents

Total: 0
No documents available.